In prostate cancer, BTG2 is a target of miR‐32, miR‐21, and its suppression results in disease initiation and progression, therapy resistance, and metastasis (Coppola et al., 2013; Jalava et al., 2012). The gene discussed is BTG2; the disease is prostate carcinoma.